Quentin Pankhurst
Prof.
Quentin Pankhurst is a Professor of
Physics, Director Institute of Biomedical Engineering
and Director of the Healthcare Biomagnetics Laboratory at
University College London – one of the top universities in the
UK, and consistently rated one of the top 20 highest education
institutions in the world. Previously, in 2008, he was the
Director of the Davy-Faraday Research Laboratory at the Royal
Institution of Great Britain (in Mayfair, London), where he
held a position once held by such luminaries as Michael
Faraday and Ernest Rutherford. On his return to UCL in 2011,
he set up the UCL Institute of Biomedical Engineering, a
cross-faculty institute that brought together 250 PIs and
their teams – more than a thousand researchers in total – in
common programmes based on translational research and
experimental medicine.
Quentin’s work in bio- and nanomagnetism is directed towards making practical advances in the use of magnetic nanoparticles in healthcare. In his career to date he has published more than 250 papers that have been cited more than 13,500 times, and he has generated more than £45M in research grant income and investment. He is a co-inventor on 12 patent families with 80+ national filings covering applications in magnetic sensing, heating and actuation; and he is the co-founder of three spinout companies: Endomagnetics Ltd (Apr. 2007); Resonant Circuits Limited (Sept. 2009); and MediSieve Ltd (Apr. 2014). Together, these companies employ more than 25 full-time staff; and one of them, Endomagnetics Ltd, recorded an annual turnover in 2017/18 of more than £6.0M. Quentin was born and raised in New Zealand, and has lived in England since 1983.
Quentin’s work in bio- and nanomagnetism is directed towards making practical advances in the use of magnetic nanoparticles in healthcare. In his career to date he has published more than 250 papers that have been cited more than 13,500 times, and he has generated more than £45M in research grant income and investment. He is a co-inventor on 12 patent families with 80+ national filings covering applications in magnetic sensing, heating and actuation; and he is the co-founder of three spinout companies: Endomagnetics Ltd (Apr. 2007); Resonant Circuits Limited (Sept. 2009); and MediSieve Ltd (Apr. 2014). Together, these companies employ more than 25 full-time staff; and one of them, Endomagnetics Ltd, recorded an annual turnover in 2017/18 of more than £6.0M. Quentin was born and raised in New Zealand, and has lived in England since 1983.
Conference
Prof Pankhurst runs research
programmes in bio- and nanomagnetism aimed at making practical
advances in the use of magnetic nanoparticles in healthcare.
These include a medical tool for breast cancer staging; a
molecular imaging microscope for living cells; and the
development of multi-functional nanoparticles for therapy and
diagnostics
In May 2008, UCL and the Royal
Institution of Great Britain entered into a five-year
programme of Joint Research Activities in healthcare
biomagnetics, led by Quentin Pankhurst, who was both appointed
as Director of the Davy-Faraday Research Laboratory at the RI,
and retained as a part-time Professor of Physics at UCL. At
the RI, Pankhurst runs research programmes in bio- and
nanomagnetism aimed at making practical advances in the use of
magnetic nanoparticles in healthcare. These include medical
imaging devices, targeted regenerative medicine, molecular
imaging microscopy for living cells, and the development of
multi-functional nanoparticles for therapy and diagnostics.
Pankhurst is also a founder and the current CTO of
Endomagnetics Ltd, a spin-out company which in 2010 gained a
CE mark for, and started selling, the SentiMag - an
intra-operative medical device for breast cancer surgery